Article Text

Download PDFPDF

Response to: ‘Comment on: ‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’ by Yang et al
  1. Sara Sabbagh1,
  2. Iago Pinal Fernandez1,
  3. Frederick W Miller2,
  4. Lisa G Rider2,
  5. Andrew Lee Mammen1
  1. 1 Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
  2. 2 Environmental Autoimmunity Group, National Institute of Environmental Health Sciences/National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland, USA
  1. Correspondence to Dr Andrew Lee Mammen, NIAMS/NIH, Bethesda, MD 20892, USA; andrew.mammen{at}

Statistics from

We are grateful for the interest in our work1 shown by Drs Yang and Liang. In their correspondence regarding this work,2 they raise concerns about (1) the association between anti-Ro52 autoantibodies and interstitial lung disease (ILD) in juvenile polymyositis (JPM) and juvenile connective tissue disease–myositis (JCTM), (2) the appropriateness of adjusting for duration of follow-up instead of length …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles